Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection
Open Access
- 7 October 2002
- journal article
- clinical trial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (21) , 13747-13752
- https://doi.org/10.1073/pnas.202372199
Abstract
Potent antiretroviral therapy (ART) suppresses HIV-1 viral replication and results in decreased morbidity and mortality. However, prolonged treatment is associated with drug-induced toxicity, emergence of drug-resistant viral strains, and financial constraints. Structured therapeutic interruptions (STIs) have been proposed as a strategy that could boost HIV-specific immunity, through controlled exposure to autologous virus over limited time periods, and subsequently control viral replication in the absence of ART. Here, we analyzed the impact of repeated STIs on virological and immunological parameters in a large prospective STI study. We show that: (i) the plateau virus load (VL) reached after STIs correlated with pretreatment VL, the amount of viral recrudescence during the treatment interruptions, and the off-treatment viral rebound rate; (ii) the magnitude and the breadth of the HIV-specific CD8+ T lymphocyte response, despite marked interpatient variability, increased overall with STI. However, the quantity and quality of the post-STI response was comparable to the response observed before any therapy; (iii) individuals with strong and broad HIV-specific CD8+ T lymphocyte responses at baseline retained these characteristics during and after STI; (iv) the increase in HIV-specific CD8+ T lymphocyte frequencies induced by STI was not correlated with decreased viral set point after STI; and (v) HIV-specific CD4+ T lymphocyte responses increased with STI, but were subsequently maintained only in patients with low pretreatment and plateau VLs. Overall, these data indicate that STI-induced quantitative boosting of HIV-specific cellular immunity was not associated with substantial change in viral replication and that STI was largely restoring pretherapy CD8+ T cell responses in patients with established infection.Keywords
This publication has 38 references indexed in Scilit:
- Human Immunodeficiency Virus-Specific CD8+T-Cell Responses Do Not Predict Viral Growth and Clearance Rates during Structured Intermittent Antiretroviral TherapyJournal of Virology, 2002
- Decay Kinetics of Human Immunodeficiency Virus-Specific CD8+T Cells in Peripheral Blood after Initiation of Highly Active Antiretroviral TherapyJournal of Virology, 2001
- Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 InfectionJournal of Virology, 2001
- Cytotoxic T Lymphocyte Responses to Human Immunodeficiency Virus: Control and EscapeThe International Journal of Cell Cloning, 2000
- The Relationship between T Cell Proliferative Responses and Plasma Viremia during Treatment of Human Immunodeficiency Virus Type 1 Infection with Combination Antiretroviral TherapyThe Journal of Infectious Diseases, 2000
- HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatmentAIDS, 1999
- Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNAScience, 1998
- Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of DefectsScience, 1996
- Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in PlasmaScience, 1996
- Phototyping: comprehensive DNA typing for HLA‐A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence‐specific primers (PCR‐SSP)Tissue Antigens, 1995